Zydus Lifesciences Ltd has received final approvals from the United States Food and Drug Administration (USFDA) to manufacture and market dexamethasone tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg and dexamethasone tablets USP, 2 mg.
Dexamethasone is used to treat different conditions, such as inflammation (swelling), severe allergies, adrenal problems, arthritis, asthma, blood or bone marrow problems, kidney problems, skin conditions, and flare-ups of multiple sclerosis.
As per the company’s statement, the products will be manufactured at the group’s formulation manufacturing facility in Baddi, Himachal Pradesh.
Zydus Lifesciences stock rose by 1.31 per cent at ₹802 as of 2.50 pm. The stock had hit a 52-week high on February 6, at ₹809.20.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.